J&J Stance on Biosimilar Naming Shows Growing Industry Rift on Issue

Drug Industry Daily
A A
Highlighting a growing dispute in the pharmaceutical industry, Johnson & Johnson is arguing that biosimilars should have international non-proprietary names (INN) that are similar to, but distinguishable from, reference products.

To View This Article:

Login

Subscribe To Drug Industry Daily